Active substances: glucose, sodium chloride, sodium acetate trihydrate, potassium chloride, magnesium chloride hexahydrate
In this leaflet, GNAK, solution for infusion will be referred to as GNAK.
GNAK is an aqueous solution of the following substances:
Glucose is one of the sources of energy for the body. This infusion solution provides 200 kilocalories per liter. Sodium, potassium, magnesium, chloride, and acetate are chemical substances found in the blood. GNAK is used as a source of fluids and chemicals, and as a source of carbohydrates (sugar), if the patient is unable to eat or drink normally.
You should tell your doctor if you have or have had any of the following conditions:
During the administration of this infusion, the doctor will take blood and urine samples to examine:
GNAK contains sugar (glucose) and may cause an increase in blood sugar levels (hyperglycemia). This is especially important in patients with diabetes. In such cases, the doctor may:
If long-term treatment with GNAK is required, the doctor will also administer other types of infusions to the patient. These will meet the body's needs for other chemical and nutritional components.
Special caution and close monitoring are required when administering GNAK to children. Newborns, especially premature and low-birth-weight infants, are more susceptible to low or high blood sugar levels due to glucose infusion. Low blood sugar levels in newborns can cause prolonged seizures, coma, and brain damage. High blood sugar levels are associated with brain hemorrhage, later onset of bacterial and fungal infections, gastrointestinal infections, visual impairment, respiratory disorders, prolonged hospital stay, and death. Children and adolescents should be closely monitored. In cases where normal regulation of water content in the blood is disrupted by increased secretion of antidiuretic hormone (ADH), infusion of fluids with low sodium chloride concentration may lead to low sodium levels in the blood (hyponatremia). This can cause headache, nausea, seizures, lethargy, coma, brain edema, and death, so these symptoms are considered a medical emergency.
You should tell your doctor or nurse about all medicines you are taking or have recently taken, as well as any medicines you plan to take. It is not recommendedto take the following medicines while taking GNAK:
Other medicines that may interact with GNAK or be affected by it:
Taking certain medicines may increase the risk of side effects due to low sodium levels in the blood. These medicines include:
You should ask your doctor what you can eat or drink.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, ask your doctor for advice before taking this medicine. The doctor will decide whether you can take GNAK if you are pregnant or breastfeeding.
This medicine does not affect your ability to drive or use machines.
GNAK is administered by a doctor or nurse. The dose of the medicine and the duration of administration are determined by the doctor. This depends on the patient's age, weight, and clinical condition, as well as any concurrent treatment. The doctor may check the levels of salts (electrolytes) and sugar (glucose) in the blood.
GNAK is usually administered through a plastic tube connected to a needle inserted into a vein. Typically, this solution is administered into a vein in the arm. However, the doctor may order a different method of administration. GNAK MUST NOT be administered under the skin (subcutaneously). Any unused solution should be discarded. GNAK MUST NOT be administered from a partially used bag. Due to the glucose content, this solution MUST NOT be administered through the same infusion set as whole blood (blood transfusion). This may cause damage or clumping of red blood cells.
In case of administration of too much GNAK (overdose) or too rapid administration, the following symptoms may occur:
If you experience any of these symptoms, you should immediately inform your doctor. The infusion will be stopped, and the doctor will treat the symptoms accordingly. If another medicine has been added to GNAK and an overdose has occurred, this additional medicine may also cause symptoms. You should read the Patient Information Leaflet accompanying the added medicine to learn about possible symptoms.
The decision to stop the infusion is made by the doctor. If you have any further questions about the use of this medicine, ask your doctor or nurse.
Like all medicines, GNAK can cause side effects, although not everybody gets them. The frequency of side effects is unknown (cannot be estimated from the available data).You should immediately inform your doctor or nurse if you experience any of the following symptoms. These may be symptoms of a very severe or even life-threatening allergic reaction (hypersensitivity):
Treatment will depend on the symptoms.
If another medicine has been added to the infusion solution, it may also cause side effects. These will depend on the medicine added. You should read the Patient Information Leaflet accompanying the added medicine to learn about possible symptoms.
If you experience any side effects, including any not listed in this leaflet, you should tell your doctor or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children. DO NOT use GNAK after the expiry date stated on the bag after "Expiry date". The expiry date refers to the last day of the month stated. DO NOT store above 25°C. DO NOT use GNAK if it contains visible particles or if the packaging is damaged in any way.
The active substances of GNAK are:
Other ingredients are:
GNAK, solution for infusion is a clear solution, free from visible particles. It is available in polyolefin-polyamide plastic bags (Viaflo). Each bag is placed in a closed, protective, outer plastic packaging. Bag size: 1000 ml. Bags are supplied in cardboard boxes. Each cardboard box contains one of the following numbers of bags:
Marketing authorization holder: Baxter Polska Sp. z o.o., ul. Kruczkowskiego 8, 00-380 Warsaw. Manufacturer: Bieffe Medital Sabiñànigo, Ctra de Biescas-Senegüe, 22666 Sabiñanigo (Huesca), Spain.
Bulgaria: GNAK 50 mg/ml solution for infusion, Croatia: GNAK 50 mg/ml solution for infusion, Czech Republic: GNAK 50 mg/ml infusion solution, Cyprus: Maintelyte 50 mg/ml solution for infusion, Denmark: Glucose-Na-K Baxter 50 mg/ml, infusion fluid, solution, Spain: Maintelyte Solution for perfusion, Finland: Glucose-Na-K Baxter 50 mg/ml infusion fluid, solution, France: MAINTELYTE solution for perfusion, Greece: Maintelyte 50 mg/ml solution for infusion, Germany: Maintelyte 50 mg/ml Infusion solution, Ireland: Maintelyte solution for infusion, Italy: GNAK 50 mg/ml Solution for infusion, Malta: Maintelyte solution for Infusion, Netherlands: Maintelyte, solution for infusion, Poland: GNAK, Portugal: GNAK 50 mg/ml Solution for perfusion, Romania: GNAK 50 mg/ml Solution for infusion, Slovenia: GNAK solution for infusion, Slovakia: GNAK 50 mg/ml Infusion solution, Sweden: Glucose-Na-K Baxter 50 mg/ml infusion fluid, solution, United Kingdom (NI): Maintelyte solution for infusion. Date of last revision of the leaflet:March 2024. Baxter and Viaflo are trademarks of Baxter International Inc.
---------------------------------------------------------------------------------------------------------------------------Only use if the solution is clear, free from visible particles, and the container is undamaged. Administer immediately after connecting the infusion set. Do not remove the bag from the protective packaging until use. The inner bag ensures the sterility of the product. Plastic containers should not be connected in series. Such use could cause air embolism due to residual air drawn from the first container before the fluid administration from the second container is completed. Applying additional pressure on intravenous solutions contained in flexible plastic containers to increase the flow rate may cause air embolism if the container is not completely emptied of air before administration. Using infusion sets with air vents, with the air vent valve in the open position, may cause air embolism. Do not use infusion sets with air vents, with the air vent valve in the open position, with flexible plastic containers. The solution should be administered using sterile equipment and following aseptic principles. The infusion set should be pre-filled with the solution to prevent air from entering the system. Additional medicines can be added to the solution before infusion or during infusion through a self-sealing port for adding medicines. Adding medicines before administration: a. Disinfect the port for adding medicines. b. Using a syringe with a needle from 19G (1.10 mm) to 22G (0.70 mm), insert the needle into the self-sealing port for adding medicines and inject the medicine. c. Mix the solution with the medicine thoroughly. In the case of preparations with high density, such as potassium chloride, gently tap the ports with the bag in the upright position and mix. Note: Do not store bags containing added medicines. Adding medicines during administration: a. Close the infusion set clamp. b. Disinfect the port for adding medicines. c. Using a syringe with a needle from 19G (1.10 mm) to 22G (0.70 mm), insert the needle into the self-sealing port for adding medicines and inject the medicine. d. Remove the container from the stand and/or turn it upside down. e. Empty both ports by gently tapping, holding the bag upside down. f. Mix the solution with the medicine thoroughly. g. Return the container to its previous position, re-open the clamp, and continue administration.
From a microbiological point of view, the diluted product should be used immediately. If the solution is not used immediately, the user is responsible for the time and conditions of storage until use, and storage should not exceed 24 hours, at a temperature between 2°C and 8°C, unless the dilution has taken place in controlled and validated aseptic conditions.
This solution should not be mixed with other medicines without compatibility testing. You should read the instructions for the medicine to be added to the solution. Before adding the medicine, you should check if it is soluble and stable in water with a pH corresponding to the GNAK solution (pH 4.5-6.5). GNAK solutions are incompatible with blood or red blood cells, and cases of clot formation have been reported. Do not use additional medicines known to be incompatible. Baxter and Viaflo are trademarks of Baxter International Inc.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.